Dr Thomas Drake

  • Clinical Research Fellow (Clinical Research Garscube)

Publications

List by: Type | Date

Jump to: 2022 | 2021
Number of items: 3.

2022

Leslie, J. et al. (2022) CXCR2 inhibition enables NASH-HCC immunotherapy. Gut, (doi: 10.1136/gutjnl-2021-326259) (PMID:35477863) (Early Online Publication)

2021

Pauley, E., Drake, T. M., Sigfrid, L., Lone, N., Harrison, E. M., Baillie, J. K., Scott, J. T. , Walsh, T. S., Semple, M. G. and Docherty, A. B. (2021) Recovery from Covid-19 critical illness: a secondary analysis of the ISARIC4C CCP-UK cohort study and the RECOVER trial. Journal of the Intensive Care Society, (doi: 10.1177/17511437211052226) (Early Online Publication)

Haq, M. I. et al. (2021) Effect of hepatocellular carcinoma surveillance programmes on overall survival in a mixed cirrhotic UK population: a prospective, longitudinal cohort study. Journal of Clinical Medicine, 10(13), 2770. (doi: 10.3390/jcm10132770) (PMID:34202593) (PMCID:PMC8269358)

This list was generated on Sun Oct 2 19:29:56 2022 BST.
Jump to: Articles
Number of items: 3.

Articles

Leslie, J. et al. (2022) CXCR2 inhibition enables NASH-HCC immunotherapy. Gut, (doi: 10.1136/gutjnl-2021-326259) (PMID:35477863) (Early Online Publication)

Pauley, E., Drake, T. M., Sigfrid, L., Lone, N., Harrison, E. M., Baillie, J. K., Scott, J. T. , Walsh, T. S., Semple, M. G. and Docherty, A. B. (2021) Recovery from Covid-19 critical illness: a secondary analysis of the ISARIC4C CCP-UK cohort study and the RECOVER trial. Journal of the Intensive Care Society, (doi: 10.1177/17511437211052226) (Early Online Publication)

Haq, M. I. et al. (2021) Effect of hepatocellular carcinoma surveillance programmes on overall survival in a mixed cirrhotic UK population: a prospective, longitudinal cohort study. Journal of Clinical Medicine, 10(13), 2770. (doi: 10.3390/jcm10132770) (PMID:34202593) (PMCID:PMC8269358)

This list was generated on Sun Oct 2 19:29:56 2022 BST.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • In-vivo efficacy with an anti-PD1 Ab in BCAT/MYC/BCL9 DKO mice available at the Beatson Institute
    Aligos Therapeutics Ind
    2021 - 2022